RCE · ASX

Recce Pharmaceuticals Ltd. (ASX:RCE)

AU$0.28

 -0.005 (-1.754%)
ASX:Live
09/05/2025 04:10:18 PM
Hammer Bearish HALO Ords HALO Consensus Value HALO Capital Efficiency GROWTH AUS +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RCE Overview

RCE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About RCE

Website

Recce Pharmaceuticals Ltd.

Telephone

61.2.9256.2505

Address

Level 23 180 George Street Salesforce Tower Sydney, New South Wales (NSW) 2000

Description

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.

RCE Price Chart

Key Stats

Market Cap

AU$82.51M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.28 - 0.66

Trade Value (12mth)

AU$19,147.00

1 week

-1.72%

1 month

-11.46%

YTD

-41.28%

1 year

-55.73%

All time high

1.84

Key Fundamentals

EPS 3 yr Growth

15.80%

EBITDA Margin

N/A

Operating Cashflow

-$13m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-25.60

Quick Ratio

0.30

Other Data

Shares on Issue (Fully Dilluted)

231m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.08

RCE Announcements

Latest Announcements

Date Announcements

05 May 25

Canadian R&D Rebate Received

×

Canadian R&D Rebate Received

30 April 25

Extension of Entitlement Offer Closing Date

×

Extension of Entitlement Offer Closing Date

30 April 25

Update - Proposed issue of securities - RCE

×

Update - Proposed issue of securities - RCE

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 April 25

Recce Enters into USA Department of Defense R&D Agreement

×

Recce Enters into USA Department of Defense R&D Agreement

23 April 25

Investor Webinar Recording Available

×

Investor Webinar Recording Available

23 April 25

Ceasing to be a substantial holder from MQG

×

Ceasing to be a substantial holder from MQG

22 April 25

Phase II Clinical Trial Receives Additional Approval for DFI

×

Phase II Clinical Trial Receives Additional Approval for DFI

22 April 25

Entitlement Offer - Offer Booklet and Access Letter

×

Entitlement Offer - Offer Booklet and Access Letter

22 April 25

Entitlement Offer - Notification to Ineligible Shareholders

×

Entitlement Offer - Notification to Ineligible Shareholders

17 April 25

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

17 April 25

Placement Settlement Completed

×

Placement Settlement Completed

17 April 25

Cleansing Notice

×

Cleansing Notice

15 April 25

RCE Investor Webinar Presentation

×

RCE Investor Webinar Presentation

10 April 25

Proposed issue of securities - RCE

×

Proposed issue of securities - RCE

10 April 25

Placement and Entitlement Offer to Fund Phase III Trials

×

Placement and Entitlement Offer to Fund Phase III Trials

10 April 25

Cleansing Notice - Entitlement Offer

×

Cleansing Notice - Entitlement Offer

10 April 25

Equity Raising Presentation

×

Equity Raising Presentation

28 March 25

Becoming a substantial holder from MQG

×

Becoming a substantial holder from MQG

20 March 25

RCE Corporate Presentation

×

RCE Corporate Presentation

03 March 25

Key Opinion Leader Presentation

×

Key Opinion Leader Presentation

28 February 25

Appendix 4D and Interim Financial Report

×

Appendix 4D and Interim Financial Report

28 February 25

RCE Clinical Milestones Investor Webinar

×

RCE Clinical Milestones Investor Webinar

26 February 25

Japan Patent Allowance for RECCE Anti-Infectives

×

Japan Patent Allowance for RECCE Anti-Infectives

17 February 25

Positive Phase II Data from Clinical Trial of R327 Gel

×

Positive Phase II Data from Clinical Trial of R327 Gel

RCE Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.07 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.07 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.4 -19.1 -34.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.07 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.07 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.9 -18.5 -21.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.8 -11.7 -12.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.06 -0.01 -0.05 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.06 -0.01 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.0 -125.6 -224.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 178 177 179 Lock Lock Lock
Basic m Lock Lock Lock Lock 178 177 179 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 17 22 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.5 -15.7 -68.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -14 -17 -22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.3 -22.5 -26.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -14 -17 -22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.9 -22.4 -27.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -14 -17 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -4 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -13 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.7 -19.0 -35.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -13 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 3 16 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -13 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.1 -40.6 -3.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 2 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 13 3 6 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -1 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 5 16 Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 -3 -10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 -2 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.0 -124.7 -259.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -87.0 -511.7 -277.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -109.2 505.2 185.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -92.0 -444.4 0.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -71.9 -345.3 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -58.9 -335.0 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -1,170.8 -93.4 -25.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.1 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -114.4 50.6 37.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.0 0.4 0.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.0 0.4 0.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 95.1 80.2 86.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -368.2 -261.6 -86.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -87.0 -511.7 -277.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 -1.0 -0.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -109.2 505.2 185.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -109.2 505.2 185.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 941.9 1,202.2 2,446.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -941.9 -1,202.2 -2,446.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.08%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RCE Shortsell

Frequently Asked Questions

The current share price of Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.28.
The 52-week high share price for Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.66.
The 52-week low share price for Recce Pharmaceuticals Ltd. (RCE:ASX)? is AU$0.28.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not offer franking credits.
Recce Pharmaceuticals Ltd. (RCE:ASX) is classified in the Healthcare.
The current P/E ratio for Recce Pharmaceuticals Ltd. (RCE:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.